At Blood Cancers Today, our mission is to translate hematologic oncology advances into practice. In partnership with the Society of Hematologic Oncology (SOHO), we’re covering the latest news on leukemia, lymphoma, myeloma, MDS, and MPNs.
Patients with Richter transformation had improved outcomes when treated with venetoclax-based treatment regimens.
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Dr. Colla describes her current research at the MD Anderson Cancer Center, such as developing new therapeutic approaches to MDS.
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
Raajit Rampal, MD, PhD, and the “Blood Cancer Talks” hosts discuss the diagnosis and management of essential thrombocythemia.
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices, featuring exclusive expert interviews.
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and CAR-T
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
Axicabtagene ciloleucel led to “continued durable responses” in patients with relapsed/refractory indolent non-Hodgkin lymphoma in the ZUMA-5 trial.
